MiMedx Group (MiMedx Group) Earnings per Share (Diluted) : $0.38 (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Earnings per Share (Diluted)?

MiMedx Group's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.39. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38.

MiMedx Group's EPS (Basic) for the three months ended in Dec. 2023 was $0.40. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.40.

MiMedx Group's EPS without NRI for the three months ended in Dec. 2023 was $0.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.39.

During the past 13 years, MiMedx Group's highest 3-Year average EPS without NRI Growth Rate was 124.40% per year. The lowest was -397.80% per year. And the median was 28.40% per year.

MiMedx Group Earnings per Share (Diluted) Historical Data

The historical data trend for MiMedx Group's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Earnings per Share (Diluted) Chart

MiMedx Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-0.24

-0.77

-0.15

-0.33

0.37

MiMedx Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.02	-0.06	-0.01	0.06	0.39

Competitive Comparison of MiMedx Group's Earnings per Share (Diluted)

For the Biotechnology subindustry, MiMedx Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiMedx Group's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where MiMedx Group's PE Ratio falls into.

MiMedx Group Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

MiMedx Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(67.439	-	6.753)	/	145.962
	=	0.42

MiMedx Group's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(62.688	-	1.569)	/	146.228
	=	0.42

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.38

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

MiMedx Group (NAS:MDXG) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MiMedx Group Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

MiMedx Group (MiMedx Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062

Website

https://www.mimedx.com

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Executives

Rice Doug	officer: Chief Financial Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper	officer: Chief Executive Officer	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein	officer: EVP, Research and Development	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson	officer: Chief Financial Officer	BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan	officer: Chief Accounting Officer	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv	officer: General Counsel	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow	officer: Chief Operating Officer	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap	officer: EVP & Chief Commercial Officer	8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves	officer: SVP & Chief Compliance Officer	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner	officer: SVP, Operations & Procurement	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani	director	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604